Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 15/20 | 0.60 |
| ▸ | P2RX2 | Q9UBL9 | 15/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495617 | 0.90 | P2RX3 (0.49) | P2RX3P2RX2 | |
| SCHEMBL2171270 | 0.89 | P2RX3 (0.71) | P2RX3P2RX2HPGDS | |
| SCHEMBL1495717 | 0.88 | AKR1C3 (0.50) | P2RX3P2RX2ALDH1A1GAAHSD17B10 | |
| SCHEMBL12757607 | 0.86 | NR1I2 (0.50) | P2RX3P2RX2 | |
| SCHEMBL2170971 | 0.85 | P2RX3 (0.67) | P2RX3P2RX2 | |
| SCHEMBL12757721 | 0.82 | NAMPT (0.54) | P2RX3P2RX2 | |
| SCHEMBL12757748 | 0.81 | EPHX2 (0.48) | P2RX3P2RX2 | |
| SCHEMBL12757592 | 0.81 | P2RX3 (0.60) | P2RX3P2RX2 | |
| SCHEMBL12757691 | 0.81 | P2RX3 (0.60) | P2RX3P2RX2HPGDS | |
| SCHEMBL12757542 | 0.81 | WDR5 (0.42) | P2RX3P2RX2ALDH1A1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | claimed |
| CN-104058999-A | Amide Compounds, Compositions And Uses Thereof | RENOVIS INC | 2014-09-24 | — | — | CN | claimed |
| CN-101981003-B | Amide compounds, compositions and uses thereof | RENOVIS INC | 2014-07-02 | — | — | CN | claimed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | claimed |
| CN-101981003-A | Amide compounds, compositions and uses thereof | RENOVIS INC | 2011-02-23 | — | — | CN | claimed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| CN-104058999-A | Amide Compounds, Compositions And Uses Thereof | RENOVIS INC | 2014-09-24 | — | — | CN | disclosed |
| CN-104016907-A | Amide compounds, compositions and uses thereof | RENOVIS INC | 2014-09-03 | — | — | CN | disclosed |
| CN-101981003-B | Amide compounds, compositions and uses thereof | RENOVIS INC | 2014-07-02 | — | — | CN | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| CN-101981003-A | Amide compounds, compositions and uses thereof | RENOVIS INC | 2011-02-23 | — | — | CN | disclosed |
| EP-2262766-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | P2RX3 219/4885P2RX2 259/4885ALDH1A1 1016/4885 |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | IL1B, ADORA2B, AVPR1B | P2RX3 219/4885P2RX2 259/4885ALDH1A1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.